Trial Profile
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2019
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors AbbVie; Boehringer Ingelheim Pharmaceuticals
- 04 May 2019 Results assessing comprehensive analysis of risankizumab pharmacokinetics in healthy subjects and patients with plaque psoriasis using data across phase I-III clinical trials (NCT01577550, NCT02054481, NCT02596217, NCT02684370, NCT02672852, NCT02684357, NCT02694523) published in the Clinical Pharmacokinetics.
- 16 Mar 2019 Results characterizing the population pharmacokinetics (PK) of RZB in patients with moderate to severe chronic plaque psoriasis using phase III trial data presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 19 Dec 2018 Results assessing similarities and differences between in molecular and histopathologic profiles in skin lesions by taking data from this and other study published in the Journal of Allergy and Clinical Immunology.